CO2023002164A2 - Proteínas de unión restringidas activadas de forma condicional - Google Patents
Proteínas de unión restringidas activadas de forma condicionalInfo
- Publication number
- CO2023002164A2 CO2023002164A2 CONC2023/0002164A CO2023002164A CO2023002164A2 CO 2023002164 A2 CO2023002164 A2 CO 2023002164A2 CO 2023002164 A CO2023002164 A CO 2023002164A CO 2023002164 A2 CO2023002164 A2 CO 2023002164A2
- Authority
- CO
- Colombia
- Prior art keywords
- tumor
- binding proteins
- conditionally activated
- constructs
- restricted binding
- Prior art date
Links
- 102000014914 Carrier Proteins Human genes 0.000 title 1
- 108091008324 binding proteins Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 108700012439 CA9 Proteins 0.000 abstract 1
- 102100038078 CD276 antigen Human genes 0.000 abstract 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 abstract 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 abstract 1
- 102100035139 Folate receptor alpha Human genes 0.000 abstract 1
- 101000884279 Homo sapiens CD276 antigen Proteins 0.000 abstract 1
- 101001023230 Homo sapiens Folate receptor alpha Proteins 0.000 abstract 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 1
- 102000035195 Peptidases Human genes 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract 1
- 241000270295 Serpentes Species 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063066565P | 2020-08-17 | 2020-08-17 | |
| PCT/US2021/046217 WO2022040128A2 (en) | 2020-08-17 | 2021-08-17 | Constrained conditionally activated binding proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023002164A2 true CO2023002164A2 (es) | 2023-03-07 |
Family
ID=77655705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0002164A CO2023002164A2 (es) | 2020-08-17 | 2023-02-27 | Proteínas de unión restringidas activadas de forma condicional |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240026011A1 (enExample) |
| EP (1) | EP4196503A2 (enExample) |
| JP (1) | JP2023538366A (enExample) |
| KR (1) | KR20230048146A (enExample) |
| CN (1) | CN116419925A (enExample) |
| AR (1) | AR123266A1 (enExample) |
| AU (1) | AU2021329290A1 (enExample) |
| CA (1) | CA3191431A1 (enExample) |
| CL (1) | CL2023000477A1 (enExample) |
| CO (1) | CO2023002164A2 (enExample) |
| EC (1) | ECSP23018458A (enExample) |
| IL (1) | IL300598A (enExample) |
| MX (1) | MX2023002002A (enExample) |
| PE (1) | PE20230856A1 (enExample) |
| TW (1) | TW202214707A (enExample) |
| WO (1) | WO2022040128A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12128102B2 (en) | 2016-03-08 | 2024-10-29 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| IL302613B2 (en) | 2017-09-08 | 2025-04-01 | Maverick Therapeutics Inc | Binding proteins are activated under limited conditions |
| AR128593A1 (es) * | 2022-02-23 | 2024-05-22 | Takeda Pharmaceuticals Co | Proteínas de unión condicionalmente biespecíficas |
| WO2024040228A2 (en) * | 2022-08-19 | 2024-02-22 | Regents Of The University Of Minnesota | Cd83 binding proteins |
| WO2024040220A2 (en) * | 2022-08-19 | 2024-02-22 | Regents Of The University Of Minnesota | Cd83 binding fusion proteins |
| PE20252271A1 (es) * | 2023-01-05 | 2025-09-15 | Harpoon Therapeutics Inc | Proteina triespecifica dirigida a trop2 para el tratamiento del cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY167125A (en) | 2011-08-17 | 2018-08-13 | Glaxo Group Ltd | Modified proteins and peptides |
| MX2018010824A (es) | 2016-03-08 | 2019-05-15 | Maverick Therapeutics Inc | Proteinas de union inducibles y metodos de uso. |
| IL302613B2 (en) * | 2017-09-08 | 2025-04-01 | Maverick Therapeutics Inc | Binding proteins are activated under limited conditions |
| EP4592313A3 (en) | 2019-03-05 | 2025-11-19 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
-
2021
- 2021-08-17 US US18/021,730 patent/US20240026011A1/en active Pending
- 2021-08-17 WO PCT/US2021/046217 patent/WO2022040128A2/en not_active Ceased
- 2021-08-17 CN CN202180066644.9A patent/CN116419925A/zh active Pending
- 2021-08-17 TW TW110130298A patent/TW202214707A/zh unknown
- 2021-08-17 PE PE2023000289A patent/PE20230856A1/es unknown
- 2021-08-17 KR KR1020237009028A patent/KR20230048146A/ko not_active Withdrawn
- 2021-08-17 EP EP21766347.5A patent/EP4196503A2/en active Pending
- 2021-08-17 AU AU2021329290A patent/AU2021329290A1/en not_active Abandoned
- 2021-08-17 JP JP2023511947A patent/JP2023538366A/ja active Pending
- 2021-08-17 IL IL300598A patent/IL300598A/en unknown
- 2021-08-17 MX MX2023002002A patent/MX2023002002A/es unknown
- 2021-08-17 CA CA3191431A patent/CA3191431A1/en active Pending
- 2021-08-17 AR ARP210102304A patent/AR123266A1/es not_active Application Discontinuation
-
2023
- 2023-02-16 CL CL2023000477A patent/CL2023000477A1/es unknown
- 2023-02-27 CO CONC2023/0002164A patent/CO2023002164A2/es unknown
- 2023-03-16 EC ECSENADI202318458A patent/ECSP23018458A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR123266A1 (es) | 2022-11-16 |
| WO2022040128A3 (en) | 2022-04-07 |
| US20240026011A1 (en) | 2024-01-25 |
| EP4196503A2 (en) | 2023-06-21 |
| MX2023002002A (es) | 2023-07-06 |
| KR20230048146A (ko) | 2023-04-10 |
| ECSP23018458A (es) | 2023-04-28 |
| IL300598A (en) | 2023-04-01 |
| CL2023000477A1 (es) | 2023-11-10 |
| PE20230856A1 (es) | 2023-05-29 |
| JP2023538366A (ja) | 2023-09-07 |
| CA3191431A1 (en) | 2022-02-24 |
| WO2022040128A2 (en) | 2022-02-24 |
| CN116419925A (zh) | 2023-07-11 |
| AU2021329290A1 (en) | 2023-04-13 |
| TW202214707A (zh) | 2022-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2023002164A2 (es) | Proteínas de unión restringidas activadas de forma condicional | |
| CL2021002241A1 (es) | Proteínas de unión condicionalmente activadas restringidas (divisional de la solicitud no. 202000570) | |
| CY1123858T1 (el) | Συζευγματα αντισωματος enanti-cmet δραστικης ουσιας και μεθοδοι για τη χρηση αυτων | |
| MX2023006869A (es) | Proteinas de union condicionalmente biespecificas. | |
| CY1124747T1 (el) | Ανθρωπινα αντισωματα σε pd-1 | |
| CY1121813T1 (el) | Anti-cd38 συν κορτικοστεροειδη συν μη-κορτικοστεροειδες χημειοθεραπευτικο για θεραπεια ογκων | |
| CY1121148T1 (el) | Παραγοντες συνδεσης vegf/dll4 και χρησεις αυτων | |
| CL2018003407A1 (es) | Anticuerdos anti-pd-1, método para producir el mismo y método para usar el mismo. | |
| CO2021009693A2 (es) | Proteínas de unión a antígeno del receptor gamma anti-il2 | |
| EA201891084A1 (ru) | Антитела к il1rap, биспецифические антигенсвязывающие молекулы, которые связываются с il1rap и cd3, и их применение | |
| EA201990346A1 (ru) | Антитела к gprc5d, биспецифические антигенсвязывающие молекулы, которые связывают gprc5d и cd3, и их применение | |
| CY1117922T1 (el) | Her2/neu-eiδika αντισωματα και μεθοδοι χρησης αυτων | |
| CY1112446T1 (el) | Θεραπευτικες ουσιες που βασιζονται σε αντιγονα με ενισχυμενη δραση αdcc | |
| GT201100223A (es) | Proteínas de unión específicas y sus usos | |
| MX2016009444A (es) | Anticuerpos humanos a ligando de muerte programada 1 (pd-l1). | |
| CL2012000524A1 (es) | Anticuerpo humanizado que se une a cdcp1 humana útil en el tratamiento del cáncer; composición farmacéutica; ácido nucleico, vector de expresión y célula huésped que lo comprende; y método para producir el anticuerpo. | |
| PE20141658A1 (es) | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) | |
| BR112023002116A2 (pt) | Proteínas que se ligam a nkg2d, cd16 e egfr | |
| BR112021025645A2 (pt) | Degradação de proteína alvo de parp14 para uso em terapia | |
| MX2022005330A (es) | Moleculas de union multiespecificas con scfv en el extremo nterminal. | |
| EA201992278A1 (ru) | Способы и композиции для снижения иммуногенности | |
| MX2023010813A (es) | Anticuerpos anti-alpp/alppl2 y conjugados de anticuerpo-farmaco. | |
| MX2025000437A (es) | Inmunoconjugados de epcam y usos de estos | |
| CO2024015526A2 (es) | Complejos radiofarmacéuticos dirigidos al antígeno prostático específico de membrana y sus combinaciones | |
| CO2023014772A2 (es) | Métodos terapéuticos que usan proteínas de unión activadas condicionalmente restringidas |